Prof. Charles L. Cooney, Ph.D. | Professor of Chemical Engineering, Massachusetts Institute of Technology

Prof. Charles L. Cooney, Ph.D. | Professor of Chemical Engineering, Massachusetts Institute of Technology

Dr. Charles L. Cooney is a Professor of Chemical Engineering and Faculty Director of the Deshpande Center for Technological Innovation at the Massachusetts Institute of Technology. He is an expert in process design and development for biological products and has served as a consultant to multiple biotech and pharmaceutical companies. Prof. Cooney also sits on the boards of Polypore International, and Biocon, Ltd. (India) as well as LS9, Pronutria, and Mitra Biosciences. His research and teaching span many aspects of biochemical engineering and pharmaceutical manufacturing. Prof. Cooney holds a Master of Science degree and Doctor of Philosophy degree in biochemical engineering from the Massachusetts Institute of Technology, and his Bachelor of Science degree in chemical engineering from the University of Pennsylvania.

Jonathan J. Fleming, MPA | President & CEO, Q-State Biosciences; Independent Director

Jonathan J. Fleming, MPA | President & CEO, Q-State Biosciences; Independent Director

Jonathan Fleming is the President and CEO of Q-State Biosciences. Prior to joining Q-State Mr. Fleming had a 30 year venture capital career in starting, financing, and building neuroscience companies dedicated to drug discovery and development. Examples of companies he has been involved in starting and building include: Chairman of Synaptic Pharmaceuticals, which was acquired by Lundbeck; Chairman of Memory Pharmaceuticals, which was acquired by Hoffman La Roche; Chairman of Brain Cells; Chairman of Hypnion Pharmaceuticals which was acquired by Eli Lilly.

In addition Mr. Fleming's venture capital firm Oxford Bioscience Partners, of which he was the Managing Partner, was closely involved in the creation of the instrument by Solexa, subsequently sold to Illumina, that is used in high thru put sequencing throughout the world. Mr. Fleming's firm was also deeply involved in the creation of the high content screening market in the pharmaceutical industry by building Cellomics - now part of Thermo Fisher. Mr. Fleming was a lead director of the Board of Cellomics in the years prior to its acquisition. For the past ten years Mr. Fleming has taught the core course on life science strategy at the MIT Sloan School of Business. He is a director of Leerink Partners a highly regarded investment bank specializing in the life sciences as well as several other private life science companies.

David Furneaux | Managing Partner, Kodiak Venture Partners

David Furneaux | Managing Partner, Kodiak Venture Partners

David Furneaux is the Founder and Managing Partner of Kodiak Venture Partners. Furneaux has over 15 years of venture investing and company building experience. He focuses on a broad range of opportunities in information technology and Internet markets. Furneaux also represents Kodiak on the Boards of Application Security, BTI Systems, Lumicell Diagnostics, and Vette Corp. He is also an observer on the board for Cortina. During his career as an entrepreneur, investor and fund manager, Furneaux has been directly involved in the conception, founding, launching and operations of many high growth companies in the information technology landscape. Selected earlier investments include ALIS (Karl Zeiss), Auroranetics (Cisco), Extreme Packet Devices (PMC-Sierra), Enfora (Novatel), Philsar (IDT), RMI (Netlogic) Skystone (Cisco), Telica (Alcatel/Lucent) and Watchfire (IBM). Furneaux holds a Bachelor of Arts degree from Colorado College, where he was a member of Phi Beta Kappa.

Ganesh Kishore, Ph.D. | CEO, Malaysian Life Sciences Capital Fund and Managing Partners, Spruce Capital Partners

Ganesh Kishore, Ph.D. | CEO, Malaysian Life Sciences Capital Fund and Managing Partners, Spruce Capital Partners

Dr. Ganesh Kishore is an entrepreneur and has co-founded three successful entities since 2002.  Two of the three entities are now parts of publicly traded entities (Tata/Rallis in India and Evolva in Switzerland) while the third business entity (Mogene LC in USA) serves both as an incubator of new ideas as well as a provider of genomic services across agriculture, health care and environment.  He serves on the board of three publicly listed entities, three privately held companies and the Advisory Board of Washington University.  He is also an advisor to multinational companies and Scientific American.

Dr. Kishore has a distinguished track record of accomplishments in biotechnology research and development and business.  He left DuPont in 2007 where he was Chief Biotechnology Officer to join Malaysian Life Science Capital Fund (MLSCF) as its CEO and later co-founded Spruce Capital Partners in 2013.

After receiving a Ph.D. in biochemistry from Indian Institute of Science, Dr. Kishore received postdoctoral training in chemistry and biology and also served as a Robert A Welch Fellow at The University of Texas at Austin. He then joined Monsanto Company as a Senior Research Biochemist, responsible for developing processes for the synthesis of Aspartame, the active ingredient of Nutrasweet and Equal.  He subsequently took leadership for discovering and developing the Roundup Ready technology and ultimately the entire agricultural technologies and biotechnology for Monsanto.  He was named a Distinguished Science Fellow, the highest honor bestowed upon scientists who have made outstanding contributions to the company but also the scientific field in general, and Assistant Chief Scientist of the company.

In 2002, Dr. Kishore joined DuPont as the Chief Technology Officer for its Agriculture and Nutrition Platform and took over the role of Chief Biotechnology Officer for the company in 2005.  During his tenure at DuPont, he guided the acquisition of several key technology companies and relationships and bolstered the biotech competence within the company.

Derek Norman | Managing Director, Syngenta Ventures

Derek Norman | Managing Director, Syngenta Ventures

Derek Norman is a Managing Director at Syngenta Ventures. He joined Syngenta Ventures in 2009 as one of the founding members. Prior to Syngenta, he was with Hatteras Ventures Partners, which invests primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, heathcare IT, and related opportunities in human medicine. Before joining Hatteras, Derek worked at Dean & Co., a strategy consulting firm. Derek serves as a director on the boards of Biognosys and two other undisclosed investments, and he is an observer to the board of Illumitex. He was an observer to the board of Marrone Bio Innovations prior to its IPO in 2013. Derek holds a B. S. degree in chemistry, with Honors, from Stanford University, a Ph.D. degree in Chemistry and Chemical Biology from Harvard University, and he is a member of Phi Beta Kappa.

Neil Renninger | CEO, Ripple Foods

Neil Renninger | CEO, Ripple Foods

Dr. Neil Renninger is an Entrepreneur-in-Residence at Khosla Ventures. Dr. Renninger co-founded Amyris, Inc. in 2003 and served as its Chief Technical Officer from 2008 to 2013. Dr. Renninger also sat on the Board of Directors at Amyris, Inc., from 2003 to 2008, and from 2011 to 2013. He has a cross-disciplinary understanding of both the micro-world of strain engineering and the macro-world of chemical engineering, and has been recognized as one of the world’s top innovators under the age of 35 by Technology Review Magazine. Dr. Renninger holds a Master of Science degree in Environmental Engineering and a Doctor of Philosophy degree in Chemical Engineering from the University of California, Berkeley, and a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology.

Prof. James Swartz, Ph.D. | Professor of Bioengineering and Chemical Engineering, Stanford University; Co-Founder

Prof. James Swartz, Ph.D. | Professor of Bioengineering and Chemical Engineering, Stanford University; Co-Founder

Dr. James Swartz is a Co-Founder of GreenLight Biosciences and a Professor in the Departments of Bioengineering and Chemical Engineering at Stanford University. Prof. Swartz has over twenty years of industrial experience at Eli Lilly and Genentech in the genetic engineering of recombinant organisms, and in the development of large scale processes for recombinant protein production. His research seeks to reproduce and direct complex metabolism in a cell-free environment. Prof Swartz is also a co-founder of Sutro Biopharma, Inc. and of Bullet Biotechnology. He also serves on the Board of Directors for Sutro Biopharma. He is a co-author or inventor for numerous scientific publications and patents related to large scale protein production as well as cell-free protein synthesis. Prof. Swartz holds a Master and Doctorate of Science degree in Chemical Engineering and Biochemical Engineering from the Massachusetts Institute of Technology, and a Bachelor of Science degree in Chemical Engineering from the South Dakota School of Mines.